WHO Approved, Sinopharm Vaccine Made In China Can Enter Covax



UMMATIMES - The World Health Organization (WHO) approved the Sinopharm vaccine from China for emergency use.

The agreement allows the Sinopharm vaccine to enter Covax. "This expands the list of Covid 19 vaccines that Covax can buy," said WHO Director General Tedros Adhanom Ghebreyesus, quoted by ABC News, Saturday (8/5).

To note, WHO has provided emergency approval for the COVID-19 vaccine developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, and Moderna.

The decision to approve the Sinopharm vaccine was taken by a WHO technical advisory group that began meeting on April 26, 2021 to review the latest clinical data as well as Sinopharm's manufacturing practices.

Tedros said that after Sinopharm was approved, the Expert Strategic Advisory Group (SAGE) recommended that adults over 18 receive two doses of Sinopharm vaccine.

SAGE found a 78.1 percent efficacy after examining two doses in a phase 3 clinical trial.

Previously, the Beijing Biological Products Institute, which developed the Sinopharm vaccine, has announced that its efficacy has reached 79.34 percent.

According to an ABC News report, China has deployed about 65 million doses of Sinopharm vaccine and more than 200 million doses of Sinovac injections.

Both of them have been exported to many countries, especially in Latin America, Asia and Africa.